Frontline Lenvatinib Plus Pembrolizumab Produces Superior Responses Vs Sunitinib in Advanced RCC

Lenvatinib plus pembrolizumab demonstrated improved overall response rates compared with sunitinib monotherapy in treatment-naïve patients with advanced renal cell carcinoma regardless of risk status or PD-L1 expression.

Related Keywords

United States ,America ,Lenvatinib Lenvima ,International Metastatic ,Kidney Cancer Research Summit ,Database Consortium ,Memorial Sloan Kettering Cancer Center ,Cancer Research ,Western Europe ,North America ,Robertj Motzer ,D ,Lenvatinib Pembrolizumab ,Phase 3 Clear Study Nct02811861 ,Renal Cell Carcinoma ,2023 Kidney Cancer Research Summit ,